Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 146

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 146
---
e of LB-102.For additional information, see “Business—License and Other Agreements—Royalty Agreements.” As of December 31, 2024, certain of our former and current officers and their affiliates held 1.27% of the future royalties. Components of Results of Operations Revenue To date, we have not recognized any revenues, including revenues from product sales. We do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for LB-102or any future product candidates are successful and result in regulatory approval, or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all. Operating Expenses Research and Development Expenses Research and development expenses consist primarily of costs incurred for the development of LB-102,which include:

| • |     | personnel expenses, including salaries, benefits, and stock-based compensation expense for our employees engaged 
 in research and development functions;                                                                           |

| • |     | expenses incurred in connection with the preclinical and clinical development of 
 LB-102, including under agreements with clinical sites and CROs;                 |

| • |     | formulation costs and chemistry, manufacturing and controls, or CMC, costs including formulation and active              
 pharmaceutical ingredients process development, analytical and quality infrastructure build-out, and validation support; |

| • |     | expenses incurred under agreements with consultants engaged in research and development functions; and |

| • |     | expenses related to regulatory affairs. |

We expense research and development costs in the periods in which they are incurred. Costs for certain activities are recognized based on an evaluation of the progress to completion of specific tasks, using information provided to us by our vendors and analyzing the progress of our clinical trials or other services performed. Significant judgment and estimates are made in determining the accrued expense balances at the end of any reporting period. Research and development activities are central to our business model. We expect our research and development expenses to increase substantially for the foreseeable future as we advance LB-102and any of our future product candidates into and through later stage clinical trials, pursue regulatory approval of our product candidates, build our operational and commercial capabilities for supplying and marketing our products, if approved, and expand our pipeline of product candidates. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming. Furthermore, product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical